Health & Research Goals
Adipotide
Adipotide (FTPP — Fat-Targeted Proapoptotic Peptide)
Primary Description
Adipotide is a chimeric peptidomimetic engineered to selectively destroy the blood vessels supplying white adipose tissue, triggering ischemic apoptosis of fat cells. Developed at MD Anderson Cancer Center, it produced dramatic weight loss results in obese primates — approximately 11% body weight loss in 28 days with simultaneous improvement in insulin sensitivity. Clinical development was halted due to nephrotoxicity concerns, but it remains one of the most discussed high-risk, high-curiosity compounds in the biohacker research community for its uniquely targeted fat-destruction mechanism.
Key Benefits
- Targeted pro-apoptotic signaling in fat cells via PROHIBITIN receptor
- Visceral adipose tissue reduction without affecting lean mass
- Fat loss acceleration with caloric restriction
Lyophilized powder requires reconstitution with bacteriostatic water. Degraded by renal D-amino acid oxidase — kidney is the primary site of catabolism. D-amino acid component of the proapoptotic sequence confers resistance to standard proteolysis.
Demonstrated Effects
- Selectively targets and eliminates blood vessels supplying white adipose tissue
- Induces ischemic apoptosis in fat cells without affecting other tissue types
- Produced approximately 11% body weight loss in 28 days in obese primates
- Reduces both subcutaneous and visceral adipose tissue
- Improves insulin sensitivity — rapid metabolic effect observed even before significant fat mass loss
- Reduces pro-inflammatory adipokines (TNF-α, IL-6, MCP-1) as fat mass decreases
- Does not affect lean muscle mass in preclinical models
- Potential to target specific problem fat deposits not responsive to diet or exercise
Proposed Mechanisms of Action
1. Prohibitin-Targeted Vascular Homing
The CKGGRAKDC targeting sequence binds to prohibitin — a protein selectively expressed on the luminal surface of blood vessels within white adipose tissue. This gives Adipotide its tissue specificity: it homes to fat vasculature and not to vessels supplying other organ systems under normal conditions.
Determines the selectivity of fat targeting — this is what makes Adipotide unique among fat loss compounds.
2. Mitochondrial Membrane Disruption and Apoptosis
Once internalized into prohibitin-expressing endothelial cells, the D(KLAKLAK)2 proapoptotic sequence disrupts mitochondrial membranes, triggering programmed cell death (apoptosis) in fat blood vessel endothelial cells. This cuts off the nutrient supply to white adipose tissue, leading to ischemic fat cell death.
The execution mechanism — converts the targeting into actual fat cell elimination via ischemia.
3. Adipokine Reduction and Anti-Inflammatory Effect
As white adipose tissue is eliminated, pro-inflammatory cytokine production from fat cells (TNF-α, IL-6, MCP-1) decreases and anti-inflammatory IL-10 increases. Reduced fat mass leads to lower systemic inflammation.
Secondary benefit — improved inflammatory profile and insulin sensitivity as direct consequences of fat reduction.
Research Evidence & Clinical Data
Investigated Applications
Targeted Fat Reduction
Anecdotal: EmergingThe primary area of community interest. Biohackers are drawn to Adipotide's mechanism — unlike GLP-1 agonists or metabolic peptides that reduce overall caloric balance, Adipotide physically destroys fat vasculature. The possibility of eliminating specific stubborn fat deposits is a major draw. However, self-experimentation is rare and considered extreme even within biohacking circles given the nephrotoxicity profile.
Preclinical basis: Landmark Barnhart et al. 2011 Science paper: obese rhesus monkeys lost ~11% body weight in 28 days. Obese mice showed ~30% fat mass reduction in earlier studies.
Insulin Resistance and Metabolic Improvement
Anecdotal: LimitedPrimate studies showed improvements in insulin sensitivity occurring rapidly after treatment — and notably, before significant weight loss had accumulated. This suggests a direct metabolic effect beyond simple fat mass reduction, possibly mediated by reduced inflammatory cytokine output from shrinking adipose tissue.
Preclinical basis: Kim et al. demonstrated glucose handling improvements in adipocytes occurring almost immediately following Adipotide treatment, preceding fat cell volume changes.
Scientific References
- 1.Barnhart et al. (2011). A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese MonkeysScience Translational Medicine2011
Landmark primate study showing ~11% body weight loss in 28 days, MRI-confirmed visceral and subcutaneous fat reduction, improved insulin sensitivity, and identification of reversible nephrotoxicity as the key safety concern.
- 2.
- 3.
Safety Profile
Common Side Effects
- Nephrotoxicity — elevated serum creatinine and BUN; proximal tubular injury (primary reason clinical development was halted)
- Increased urine output / polyuria during treatment
- Mild dehydration tendency — requires proactive hydration
- Fatigue during treatment cycle
- Injection site reactions (redness, swelling, tenderness)
- Nausea reported in some animal subjects
- Potential for systemic inflammatory response as fat tissue is rapidly destroyed
Contraindications
- ANY degree of pre-existing kidney disease or impaired renal function — absolute contraindication
- Concurrent use of other nephrotoxic compounds (NSAIDs, aminoglycosides, contrast agents)
- Dehydration or conditions causing reduced renal perfusion
- Pregnancy or breastfeeding
- Active cardiovascular disease
- Autoimmune conditions affecting vasculature
- Unknown: any condition affecting white adipose tissue distribution or vascularization
Pre-Use Screening Checklist
Mandatory baseline — any elevation in creatinine, reduced GFR, or history of kidney disease is an absolute contraindication. Adipotide is metabolized in the kidney and causes dose-dependent proximal tubular injury.
Additive nephrotoxicity risk. NSAIDs, antibiotics, and contrast agents must be absent during any Adipotide cycle.
Adequate hydration (minimum 2–3 L daily) is essential to protect renal tubular function during the cycle.
Baseline lipids, glucose, and insulin sensitivity markers allow assessment of metabolic response during treatment.
Legal & Regulatory Status
Not approved for any human use. Phase I clinical trials initiated 2011 but halted. Clinical development permanently discontinued due to nephrotoxicity. Research chemical classification only.
Prohibited. Not approved by any health authority; falls under S0 category (Non-Approved Substances) for athletes subject to WADA code.
No specific COFEPRIS ruling identified. Available as research peptide. Not approved as pharmaceutical. Human use constitutes off-label self-experimentation.
Not approved by EMA. Research use only; regulations vary by member state.
Not TGA-approved. Classified as Schedule 4 or research chemical depending on formulation context.
Research Protocols
Dosing Protocols
Preclinical-translated research protocol (most common community reference)
Subcutaneous injectionRoutes of Administration
Subcutaneous injection
Most commonStandard sub-Q injection, typically into the abdominal fat fold. Rotate injection sites to minimize local tissue effects.
Use 29–31 gauge insulin syringes. Inject slowly into pinched abdominal skin. Never inject IV.
Reconstitution Guide
Bacteriostatic water (preferred) or sterile water for injection
Add bacteriostatic water slowly down the inside wall of the vial. Do not shake — gently swirl until fully dissolved. The lyophilized powder should dissolve to a clear solution.
5 mg vial + 2.5 mL bacteriostatic water = 2 mg/mL. To draw 1 mg: pull 0.5 mL (50 units on a 100-unit insulin syringe).
Refrigerate at 2–8°C. Use within 28 days. Do not freeze reconstituted solution.
Lyophilized powder: store at -20°C (freezer) for long-term, or 2–8°C for up to 3 months.
Morning injection on an empty stomach is the standard protocol. Adequate hydration throughout the day is critical given the renal metabolism pathway.
Pharmacokinetics
| Half-Life | Not formally established in humans. Renal D-amino acid oxidase is identified as the primary catabolic enzyme for the D(KLAKLAK)2 proapoptotic component, making the kidney the rate-limiting site of metabolism and clearance. |
| Absorption | Subcutaneous injection is the standard route. Bioavailability following sub-Q injection not formally reported in published literature. |
| Distribution | Selectively homes to prohibitin-expressing endothelial cells in white adipose tissue vasculature. Confirmed distribution to white fat vascular beds in preclinical imaging studies. |
| Metabolism | Primary catabolism via renal D-amino acid oxidase acting on the D-amino acid-containing proapoptotic sequence. This renal metabolism pathway is directly linked to the observed nephrotoxicity. |
| Molecular Structure | Chimeric bipartite structure: CKGGRAKDC (cyclic, prohibitin-binding homing domain) connected via Gly-Gly linker to D(KLAKLAK)2 (amphipathic D-amino acid proapoptotic sequence). The D-enantiomer configuration resists standard proteolysis. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Kidney function (serum creatinine, BUN, urinalysis)Any elevation in creatinine above baseline, reduced urine output, or presence of protein/blood in urine requires immediate discontinuation.Check: Every 7 days during cycle
- Hydration status and urine outputReduced urine output, dark urine, or unusual thirst are early warning signs of renal stress.Check: Daily
- Body weight and compositionTrack fat vs. lean mass. Rapid weight loss beyond expected rate may indicate systemic effects.Check: Weekly
Critical Warning Signs
- Reduced urine output, dark or cloudy urine, or flank painStop Adipotide immediately. Go to urgent care or emergency room for renal function evaluation. Do not restart.Urgency: IMMEDIATE
- Elevated creatinine or BUN on lab test (any elevation above baseline)Discontinue immediately. Increase fluid intake. Follow up with physician. Document timeline for medical provider.Urgency: IMMEDIATE
- Severe fatigue, nausea, or vomiting during cycleDiscontinue use and assess kidney function labs urgently. These may be systemic signs of renal toxicity.Urgency: Within 24-48 hours
Featured in Stacking Protocols
Community-researched combinations involving this compound
BPC-157
BPC-157 Recovery StackKidney and tissue protection during Adipotide cycle
BPC-157 is discussed in community contexts as a potential renal-protective co-administration during Adipotide cycles, given its cytoprotective and angiogenic repair properties. Purely theoretical — no clinical data exists for this combination.
BPC-157 250–500 mcg sub-Q daily alongside Adipotide cycle. Theoretical only.
AOD-9604
Fat Loss Synergy StackComplementary fat loss mechanisms
Adipotide destroys fat vasculature (apoptotic); AOD-9604 promotes lipolysis and fat oxidation (metabolic). Theoretically complementary but the nephrotoxicity risk of Adipotide makes combination protocols inadvisable outside strictly controlled contexts.
Not recommended due to Adipotide safety profile. Theoretical stack only.